Literature DB >> 31155566

Synthesis and Biological Evaluation of PF-543 Derivative Containing Aliphatic Side Chain.

Seon Woong Kim1, Taeho Lee2, Yoon Sin Oh3, Sang Mi Shin4, Joo-Youn Lee5,6, Sanghee Kim5, Dong Jae Baek1, Eun-Young Park1.   

Abstract

The PF-543 is known as a potent and selective inhibitor of sphingosine kinase (SK) 1 amongst all the SK inhibitors known to date. In a recently reported study by Pfizer on the synthesis of PF-543 derivatives and the SK inhibitory effects, the introduction of propyl moiety into sulfonyl group of PF-543 in the case of 26b revealed an excellent result of 1.7 nM of IC50 of SK1, suggesting the potential substitution of chain structure for benzenesulfonyl structure. In the present work, we aimed for identification of antitumor activity and inhibitory effects of PF-543 derivative containing aliphatic long chain (similar to known SK inhibitors) on SK1. The synthesized compound 2 exhibited an inhibitory effect on SK1 in a manner similar to that of PF-543; the PF-543 derivative manifested similar antitumor activity on HT29, HCT116 (colorectal cancer cell line), and AGS (gastric cancer cell line) cells. Also, from the docking study conducted with PF-543 and compound 2, it was apparent that the aliphatic chain in compound 2 could probably replace benzenesulfonyl structure of PF-543.

Entities:  

Keywords:  PF-543; anticancer; derivative; sphingosine kinase

Mesh:

Substances:

Year:  2019        PMID: 31155566     DOI: 10.1248/cpb.c18-00724

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  4 in total

Review 1.  Inhibitors of Ceramide- and Sphingosine-Metabolizing Enzymes as Sensitizers in Radiotherapy and Chemotherapy for Head and Neck Squamous Cell Carcinoma.

Authors:  Yoshiaki Yura; Atsushi Masui; Masakazu Hamada
Journal:  Cancers (Basel)       Date:  2020-07-26       Impact factor: 6.639

2.  Verification of the Necessity of the Tolyl Group of PF-543 for Sphingosine Kinase 1 Inhibitory Activity.

Authors:  Su Bin Kim; Taeho Lee; Hong Seop Moon; Sung Hwan Ki; Yoon Sin Oh; Joo-Youn Lee; Sang-Bum Kim; Jeong-Eun Park; Yongseok Kwon; Sanghee Kim; Dong Jae Baek; Eun-Young Park
Journal:  Molecules       Date:  2020-05-27       Impact factor: 4.411

Review 3.  Antineoplastic Agents Targeting Sphingolipid Pathways.

Authors:  Alexander Kroll; Hwang Eui Cho; Min H Kang
Journal:  Front Oncol       Date:  2020-05-22       Impact factor: 6.244

4.  Determining the Anticancer Activity of Sphingosine Kinase Inhibitors Containing Heteroatoms in Their Tail Structure.

Authors:  Jitendra Shrestha; Seong Woong Kim; Su-Bin Kim; Yoon Sin Oh; Sung Hwan Ki; Taeho Lee; Sang-Bum Kim; Taeuk Park; Dong Jae Baek; Eun-Young Park
Journal:  Pharmaceutics       Date:  2022-01-10       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.